Difference between revisions of "Anal cancer"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 1: Line 1:
−
<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''-->
 
−
 
−
<!--Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].-->
 
 
{| class="wikitable" style="text-align:center; width:100%;"
 
{| class="wikitable" style="text-align:center; width:100%;"
−
! colspan="4" style="color:white; font-size:125%; background-color:#08519c" align="center" |'''Section editors'''
+
! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Page editor'''
 +
! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Section editor'''
 
|-
 
|-
 +
| style="background-color:#F0F0F0; width:15%" |coming soon
 +
| style="width:35%" |<big>Ari Seifter, MD<br>University of Illinois at Chicago<br>Chicago, IL</big>
 
| style="background-color:#F0F0F0; width:15%" |[[File:nkv.jpg|frameless|upright=0.3|center]]
 
| style="background-color:#F0F0F0; width:15%" |[[File:nkv.jpg|frameless|upright=0.3|center]]
−
| style="width:35%" |<big>[[User:Neetavenepalli|Neeta K. Venepalli, MD, MBA]]<br>Chicago, IL</big>
+
| style="width:35%" |<big>[[User:Neetavenepalli|Neeta K. Venepalli, MD, MBA]]<br>University of Illinois at Chicago<br>Chicago, IL</big>
−
| style="background-color:#F0F0F0; width:15%" |[[File:Naina Singh.JPG|frameless|upright=0.3|center]]
 
−
| style="width:35%" |<big>[[User:Nainasingh|Naina Singh, MD]]<br>Chicago, IL</big>
 
 
|-
 
|-
 
|}
 
|}

Revision as of 02:55, 6 January 2019

Page editor Section editor
coming soon Ari Seifter, MD
University of Illinois at Chicago
Chicago, IL
Nkv.jpg
 Neeta K. Venepalli, MD, MBA
University of Illinois at Chicago
Chicago, IL
9 regimens on this page
13 variants on this page


Guidelines

ESMO

NCCN

Definitive chemoradiotherapy for locally advanced disease

Capecitabine, Mitomycin, RT

back to top

Regimen

Study Evidence
Glynne-Jones et al. 2008 Phase II

Chemoradiotherapy

6-week course

References

  1. EXTRA: Glynne-Jones R, Meadows H, Wan S, Gollins S, Leslie M, Levine E, McDonald AC, Myint S, Samuel L, Sebag-Montefiore D; National Cancer Research Institute Anal Sub Group and Colorectal Clinical Oncology Group. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):119-26. Epub 2008 May 9. link to original article contains protocol PubMed

Cisplatin, Fluorouracil, RT

Fluorouracil, cisplatin, radiation therapy for anal cancer

Fluorouracil, Mitomycin, RT

Fluorouracil, mitomycin, radiation therapy for anal cancer

Radiation therapy

Radiation therapy for anal cancer

Chemotherapy for metastatic disease

Cisplatin & Fluorouracil

Fluorouracil & cisplatin for anal cancer

Retrieved from "https://hemonc.org/w/index.php?title=Anal_cancer&oldid=34198"